Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Soy isoflavone extract does not increase the intoxicating effects of acute alcohol ingestion in human volunteers

  • Martínez-Riera, R.
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Papaseit, Esther|||0000-0003-2620-4274
  • Fonseca, Francina|||0000-0002-0779-6545
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Pizarro Lozano, Nieves|||0000-0003-2671-7184
  • Torrens, Marta
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
Soy beans contain isoflavones, including daidzein and genistein, with biological activities related to therapeutic effects in reducing osteoporosis, decreasing adverse menopausal manifestations, providing protection from cardiovascular diseases, and reducing hormone-dependent cancers and age-related cognitive-decline. Daidzein has been described as inhibiting the aldehyde-dehydrogenase-2 enzyme (ALDH2), and reducing alcohol use in clinical pilot studies. Our aim was to evaluate the possible interactions between a soy extract product and alcohol in a crossover, single blind, randomized study. Ten healthy male volunteers participated in two experimental sessions: one with a single dose of alcohol (0.5 g/kg, Vodka Absolut, Sweden), and the other with four capsules of a soy extract product (Super-Absorbable Soy Isoflavones, Life-Extension, United States) and, 2 h later, the same dose of alcohol. Results showed no differences in vital signs except a slightly higher significative reduction in diastolic blood pressure at 2, 3, 4, and 8 h after administration with alcohol alone in comparison with soy extract+alcohol. Ethanol-induced subjective and adverse effects were similar for both conditions with the exception of headache (higher at 8 h after alcohol alone). Our results demonstrate that a single dose of a soy isoflavone extract did not influence alcohol pharmacokinetics and pharmacological effects and did not induce any disulfiram-reaction symptoms. Soy extract and alcohol did not interact and can be administered safely.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity

  • Rodríguez-Morató, Jose|||0000-0002-8133-9983
  • Goday Arnó, Albert|||0000-0001-7356-1595
  • Langohr, Klaus|||0000-0001-7075-9192
  • Pujadas, Mitona|||0000-0002-0506-3030
  • Civit, Ester
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Papaseit, Esther|||0000-0003-2620-4274
  • Ramon, Jose Manuel
  • Benaiges, David|||0000-0001-5411-364X
  • Castañer, Olga|||0000-0003-3169-997X
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Torre, Rafael de la|||0000-0002-6765-1866
Morbid obesity and bariatric surgery induce anatomical, physiological and metabolic alterations that may alter the body's disposition of drugs. Current literature on this topic is limited and sometimes inconsistent. Cytochrome P450 (CYP) is a superfamily of enzymes that metabolize around 75% of all marketed drugs. The purpose of this study was to evaluate the impact of body mass index and bariatric surgery on CYP activities. Firstly, we evaluated the in vivo activity of 4 major CYP isoenzymes (CYP2D6, CYP3A4, CYP2C9, and CYP1A2) in normal weight, overweight, and morbidly obese individuals. Secondly, we assessed the short- (1 month) and medium-term (6 month) effects of the most commonly employed bariatric surgery techniques (laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass) on the activity of these enzymes. CYP3A4 activity was lower in morbidly obese individuals, compared to normal-weight controls. Interestingly, bariatric surgery normalized CYP3A4 activity. In comparison with normal-weight controls, morbidly obese individuals had higher CYP2D6 activity, which was only observed in individuals with two functional alleles for this isoenzyme. Neither body mass index nor surgery had significant effects on CYP2C9 and CYP1A2 activities. Overall, no relevant differences in CYP activities were found between surgical techniques. In conclusion, further studies should evaluate whether the observed alterations in CYP3A4 activity will require dose adjustments for CYP3A4 substrates especially in morbidly obese individuals before and after bariatric surgery.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acute Effects of 2C-E in Humans, An Observational Study

  • Papaseit, Esther|||0000-0003-2620-4274
  • Olesti, Eulàlia|||0000-0001-8677-9964
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Torrens, Marta
  • Grifell, Marc|||0000-0001-9815-5761
  • Ventura, Mireia|||0000-0003-1133-6872
  • Pozo, Oscar J.|||0000-0002-1735-9728
  • de Sousa Fernandes Perna, Elizabeth B.|||0000-0001-8580-1795
  • Ramaekers, Johannes G.|||0000-0003-4553-376X
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
2,5-Dimethoxy-4-ethylphenethylamine (2C-E) is psychedelic phenylethylamine, with a chemical structure similar to mescaline, used as new psychoactive substance (NPS). It inhibits norepinephrine and serotonin uptake and, more relevant, acts as a partial agonist of the serotonin 2A (5-HT), 2B (5-HT), and (5-HT) receptors. Consumers have reported that 2C-E induces mild-moderate psychedelic effects, but its pharmacology in humans, including pharmacological effects and pharmacokinetics, have not yet studied. To assess the acute effects of 2C-E on physiological and subjective effects and evaluate its pharmacokinetics, an observational study was carried-out. Ten recreational users of psychedelics self-administered a single oral dose of 2C-E (6.5, 8, 10, 15, or 25 mg). Blood pressure and heart rate were evaluated at baseline, 2, 4, and 6 h post-administration. Three rating scales were administered to evaluate subjective effects: a set of Visual Analog Scales (VAS), the 49-item short form version of the Addiction Research Centre Inventory (ARCI), and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) at baseline, 2, 4, and 6 h after self-administration. To assess 2C-E concentrations oral fluid (saliva) was collected during 6 h. 2C-E induced primarily alterations in perceptions, hallucinations, and euphoric-mood. Saliva maximal concentrations were achieved 2 h after self-administration. Administration of oral 2C-E at recreational doses produces a group of psychedelic-like effects such to 2C-B and other serotonin-acting drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cannabinoids, from pot to lab

  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Pérez-Acevedo, Ana Pilar|||0000-0001-5647-4529
  • Hladun, Olga|||0000-0002-6230-5876
  • Torres-Moreno, M. Carmen
  • Muga, Roberto|||0000-0001-6301-431X
  • Torrens, Marta|||0000-0001-6222-4761
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
Cannabis is becoming increasingly present in our society. In recent years, the line between the natural (cannabis) and the synthetic (synthetic cannabinoids), the recreational (cannabis) and the medical (pharmaceutical cannabinoids and medical cannabis) has been crossed. In this paper we review some of the novel aspects of cannabis and cannabinoids in relation to their legal situation, changes in their composition and forms of cannabis use, the concept of medical cannabis, and synthetic cannabinoids as new psychoactive substances (NPS). We have also analyzed serious adverse reactions and intoxications associated with the use of synthetic cannabinoids, as well as the latest developments in the research of pharmaceutical cannabinoids.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Tryptophan System in Cocaine-Induced Depression

  • Fonseca, Francina|||0000-0002-0779-6545
  • Mestre-Pintó, Joan-Ignasi|||0000-0003-0387-9375
  • Gomez-Gomez, A.|||0000-0001-8172-1827
  • Martinez-Sanvisens, Diana
  • Rodríguez-Minguela, Rocío
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Langohr, Klaus|||0000-0001-7075-9192
  • Valverde, Olga|||0000-0003-2264-7852
  • Pozo, Oscar J.|||0000-0002-1735-9728
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Torrens, Marta
Major depression disorder (MDD) is the most prevalent psychiatric comorbid condition in cocaine use disorder (CUD). The comorbid MDD might be primary-MDD (CUD-primary-MDD) or cocaine-induced MDD (CUD-induced-MDD), and their accurate diagnoses and treatment is a challenge for improving prognoses. This study aimed to assess the tryptophan/serotonin (Trp/5-HT) system with the acute tryptophan depletion test (ATD), and the kynurenine pathway in subjects with CUD-primary-MDD, CUD-induced-MDD, MDD and healthy controls. The ATD was performed with a randomized, double-blind, crossover, and placebo-controlled design. Markers of enzymatic activity of indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase, kynurenine aminotransferase (KAT) and kynureninase were also established. Following ATD, we observed a decrease in Trp levels in all groups. Comparison between CUD-induced-MDD and MDD revealed significant differences in 5-HT plasma concentrations (512 + 332 ng/mL vs. 107 + 127 ng/mL, p = 0.039) and the Kyn/5-HT ratio (11 + 15 vs. 112 + 136; p = 0.012), whereas there were no differences between CUD-primary-MDD and MDD. Effect size coefficients show a gradient for all targeted markers (d range 0.72-1.67). Results suggest different pathogenesis for CUD-induced-MDD, with lower participation of the tryptophan system, probably more related to other neurotransmitter pathways and accordingly suggesting the need for a different pharmacological treatment approach.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acute Pharmacological Effects of 2C-B in Humans, An Observational Study

  • Papaseit, Esther|||0000-0003-2620-4274
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Torrens, Marta
  • Ventura, Mireia|||0000-0003-1133-6872
  • Pujadas, Mitona|||0000-0002-0506-3030
  • Torre, Rafael de la|||0000-0002-6765-1866
  • González, Débora|||0000-0002-5353-4351
2,5-dimethoxy-4-bromophenethylamine (2C-B) is a psychedelic phenylethylamine derivative, structurally similar to mescaline. It is a serotonin 5-hydroxytryptamine-2A (5-HT), 5-hydroxytryptamine-2B (5-HT), and 5-hydroxytryptamine-2C (5-HT) receptor partial agonist used recreationally as a new psychoactive substance. It has been reported that 2C-B induces mild psychedelic effects, although its acute pharmacological effects and pharmacokinetics have not yet been fully studied in humans. An observational study was conducted to assess the acute subjective and physiological effects, as well as pharmacokinetics of 2C-B. Sixteen healthy, experienced drug users self-administered an oral dose of 2C-B (10, 15, or 20 mg). Vital signs (blood pressure and heart rate) were measured at baseline 1, 2, 3, 4, and 6 hours (h). Each participant completed subjective effects using three rating scales: the visual analog scale (VAS), the Addiction Research Centre Inventory (ARCI), and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) at baseline, 2-3 and 6 h after self-administration (maximum effects along 6 h), and the Hallucinogenic Rating Scale (maximum effects along 6 h). Oral fluid (saliva) was collected to assess 2C-B and cortisol concentrations during 24 h. Acute administration of 2C-B increased blood pressure and heart rate. Scores of scales related to euphoria increased (high, liking, and stimulated), and changes in perceptions (distances, colors, shapes, and lights) and different body feelings/surrounding were produced. Mild hallucinating effects were described in five subjects. Maximum concentrations of 2C-B and cortisol were reached at 1 and 3 h after self-administration, respectively. Oral 2C-B at recreational doses induces a constellation of psychedelic/psychostimulant-like effects similar to those associated with serotonin-acting drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression

  • Fonseca, Francina|||0000-0002-0779-6545
  • Mestre-Pintó, Joan-Ignasi|||0000-0003-0387-9375
  • Rodríguez-Minguela, Rocío
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Langohr, Klaus|||0000-0001-7075-9192
  • Barbuti, Margherita
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Torrens, Marta
Major depressive disorder (MDD) and cocaine use disorder (CUD) are related with disability and high mortality rates. The assessment and treatment of psychiatric comorbidity is challenging due to its high prevalence and its clinical severity, mostly due to suicide rates and the presence of medical comorbidities. The aim of this study is to investigate differences in brain derived neurotrophic factor (BDNF) and cortisol plasmatic levels in patients diagnosed with CUD-primary-MDD and CUD-induced-MDD and also to compare them to a sample of MDD patients (without cocaine use), a sample of CUD (without MDD), and a group of healthy controls (HC) after a stress challenge. A total of 46 subjects were included: MDD (n = 6), CUD (n = 15), CUD-primary-MDD (n = 16), CUD-induced-MDD (n = 9), and 21 HC. Psychiatric comorbidity was assessed with the Spanish version of the Psychiatric Research Interview for Substance and Mental Disorders IV (PRISM-IV), and depression severity was measured with the Hamilton Depression Rating Scale (HDRS). Patients were administered the Trier Social Stress Test (TSST) before and after the biological measures, including BDNF, and cortisol levels were obtained. After the TSST, Cohen's d values between CUD-primary-MDD and CUD-induced-MDD increased in each assessment from 0.19 post-TSST to 2.04 post-90-TSST. Pairwise differences among CUD-induced-MDD and both MDD and HC groups had also a large effect size value in post-30-TSST and post-90-TSST. In the case of the BDNF concentrations, CUD-primary-MDD and CUD-induced-MDD in post-90-TSST (12,627.27 ± 5488.09 vs.17,144.84 ± 6581.06, respectively) had a large effect size (0.77). Results suggest a different pathogenesis for CUD-induced-MDD with higher levels of cortisol and BDNF compared with CUD-primary-MDD. Such variations should imply different approaches in treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effects of Mixing Energy Drinks With Alcohol on Driving-Related Skills

  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Mateus, Julián Andrés
  • Díaz-Pellicer, Patricia
  • Díaz-Baggerman, Ariadna
  • Pérez, Marta
  • Pujadas, Mitona|||0000-0002-0506-3030
  • Fonseca, Francina|||0000-0002-0779-6545
  • Papaseit, Esther|||0000-0003-2620-4274
  • Pujol Nuez, Jesús|||0000-0002-9946-4547
  • Langohr, Klaus|||0000-0001-7075-9192
  • Torre, Rafael de la|||0000-0002-6765-1866
Energy drinks (EDs) reduce sleepiness and fatigue and improve driving performance whereas alcohol does just the opposite. Although it is a trendy combination among young people, the effects of alcohol mixed with EDs on driving performance have been poorly studied. The aim was to assess if there is an interaction between the effects of both drinks on driving-related skills as well as perceptions about driving ability. We conducted a randomized, double-blind, and placebo-controlled 4-way crossover clinical trial. Participants were 16 healthy volunteers. Interventions of 60 g of ethanol and 750 mL of Red Bull (RB) were administered in 2 separated doses. Conditions were alcohol + RB placebo, alcohol + RB, alcohol placebo + RB, and both placebos. Objective performance was assessed using a tracking test and simple reaction time, N-Back, and movement estimation tasks. Additionally, willingness to drive, other subjective effects, and ethanol and caffeine blood concentrations were also measured. Alcohol increased the time outside the road in the tracking test and increased simple reaction time, but the addition of RB had no main or interaction effects on performance. Nonetheless, driving-related skills after alcohol + RB were better than after alcohol alone. Willingness to drive increased with the combination of drinks. RB also reduced alcohol-induced sedation whereas drunkenness did not change. These effects were seen even though alcohol + RB increased alcohol (14.8%) and caffeine plasma concentrations (17.6%). Mixing EDs with alcohol predisposes consumers to drive under alcohol influence, perhaps in part because EDs counteract its detrimental effects on driving-related skills. : NCT02771587.